Roivant Sciences Ltd (ROIV) is ready for next Episode as it posted an annual sales of 124,800 K

Roivant Sciences Ltd (NASDAQ: ROIV) kicked off on Monday, down -3.86% from the previous trading day, before settling in for the closing price of $11.13. Over the past 52 weeks, ROIV has traded in a range of $9.69-$13.06.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 493.24% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -114.65%. With a float of $448.17 million, this company’s outstanding shares have now reached $733.33 million.

In an organization with 908 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.77%, operating margin of 3447.71%, and the pretax margin is 3781.64%.

Roivant Sciences Ltd (ROIV) Insider Updates

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Roivant Sciences Ltd is 38.43%, while institutional ownership is 67.65%. The most recent insider transaction that took place on Jan 21 ’25, was worth 1,128,000. In this transaction President & COO of this company sold 100,000 shares at a rate of $11.28, taking the stock ownership to the 732,294 shares. Before that another transaction happened on Jan 21 ’25, when Company’s Officer proposed sale 100,000 for $11.28, making the entire transaction worth $1,128,457.

Roivant Sciences Ltd (ROIV) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -114.65% per share during the next fiscal year.

Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators

Take a look at Roivant Sciences Ltd’s (ROIV) current performance indicators. Last quarter, stock had a quick ratio of 10.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 61.98.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.66, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.09 in one year’s time.

Technical Analysis of Roivant Sciences Ltd (ROIV)

Let’s dig in a bit further. During the last 5-days, its volume was 3.0 million. That was inferior than the volume of 4.16 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 39.37%. Additionally, its Average True Range was 0.32.

During the past 100 days, Roivant Sciences Ltd’s (ROIV) raw stochastic average was set at 11.13%, which indicates a significant increase from 0.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.91% in the past 14 days, which was lower than the 28.86% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $11.67, while its 200-day Moving Average is $11.38. However, in the short run, Roivant Sciences Ltd’s stock first resistance to watch stands at $10.89. Second resistance stands at $11.08. The third major resistance level sits at $11.17. If the price goes on to break the first support level at $10.60, it is likely to go to the next support level at $10.51. Assuming the price breaks the second support level, the third support level stands at $10.32.

Roivant Sciences Ltd (NASDAQ: ROIV) Key Stats

The company with the Market Capitalisation of 7.79 billion has total of 727,950K Shares Outstanding. Its annual sales at the moment are 124,800 K in contrast with the sum of 4,349 M annual income. Company’s last quarter sales were recorded 4,480 K and last quarter income was -230,180 K.